# Eris Lifesciences (NSE: ERIS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ERIS · Pivot · prices to 21 Oct 2026

Eris Lifesciences (NSE: ERIS) closed at ₹1,119.40 on 21 Oct 2026. With a market capitalisation of ₹15,450 Cr, it ranks 422nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 24.6× trailing earnings, against a return on equity of 15.9% in FY26. Over the past year the share price has fallen 30.0%. Its 52-week range is ₹1,111.10 (19 Oct 2026) to ₹1,740.00 (9 Dec 2025); the last close is 35.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹869 Cr (+12.6% year on year) and net profit ₹144 Cr (+15.7%), on a consolidated basis. Promoters held 54.14% of the company as of 30 Jun 2026; 16.85% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,119.40 |
| Market cap | ₹15,450 Cr |
| P/E (trailing) | 24.6 |
| ROE | 15.9% (FY26) |
| ROCE | 16.0% (FY26) |
| Debt to equity | 0.59 |
| 52-week high | ₹1,740.00 (9 Dec 2025) |
| 52-week low | ₹1,111.10 (19 Oct 2026) |
| 1-year return | −30.0% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹869 Cr | +12.6% | ₹144 Cr | +15.7% | ₹10.28 |
| Q4 FY26 | ₹752 Cr | +7.1% | ₹280 Cr | +174.0% | ₹20.60 |
| Q3 FY26 | ₹801 Cr | +10.9% | ₹109 Cr | +25.1% | ₹7.32 |
| Q2 FY26 | ₹790 Cr | +6.9% | ₹134 Cr | +39.3% | ₹8.82 |
| Q1 FY26 | ₹772 Cr | +7.8% | ₹124 Cr | +38.9% | ₹8.66 |
| Q4 FY25 | ₹703 Cr | +28.4% | ₹102 Cr | +28.5% | ₹6.90 |
| Q3 FY25 | ₹722 Cr | +49.4% | ₹87 Cr | −14.3% | ₹6.15 |
| Q2 FY25 | ₹739 Cr | +46.2% | ₹96 Cr | −21.2% | ₹6.73 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹2,894 Cr | ₹375 Cr |
| FY24 | ₹2,009 Cr | ₹397 Cr |
| FY23 | ₹1,685 Cr | ₹374 Cr |
| FY22 | ₹1,347 Cr | ₹406 Cr |
| FY21 | ₹1,212 Cr | ₹355 Cr |
| FY20 | ₹1,074 Cr | ₹297 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 54.14%
- Foreign institutions: 5.75%
- Domestic institutions: 20.72%
- Non-institutions: 19.40%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Syngene International](https://app.pivotnow.in/stock/SYNGENE) | ₹399.00 | ₹16,106 Cr | 50.6 | — |
| [Poly Medicure](https://app.pivotnow.in/stock/POLYMED) | ₹1,550.00 | ₹15,711 Cr | 48.9 | — |
| [Alembic Pharmaceuticals](https://app.pivotnow.in/stock/APLLTD) | ₹799.00 | ₹15,705 Cr | 23.3 | — |
| [Onesource Specialty Pharma](https://app.pivotnow.in/stock/ONESOURCE) | ₹1,364.00 | ₹15,638 Cr | — | — |
| [Alivus Life Sciences](https://app.pivotnow.in/stock/ALIVUS) | ₹1,257.80 | ₹15,438 Cr | 27.4 | — |
| [AstraZeneca Pharma India](https://app.pivotnow.in/stock/ASTRAZEN) | ₹6,074.00 | ₹15,185 Cr | 81.2 | — |

## Questions and answers

### What is the share price of Eris Lifesciences today?

Eris Lifesciences (NSE: ERIS) last closed at ₹1,119.40 on 21 Oct 2026. Its 52-week high is ₹1,740.00 and its 52-week low is ₹1,111.10.

### What is the market cap of Eris Lifesciences?

Eris Lifesciences' market capitalisation is ₹15,450 Cr (₹15,450 Cr) at the 19 Oct 2026 close, ranking 422nd among the NSE companies Pivot tracks.

### What is the P/E ratio of Eris Lifesciences?

Eris Lifesciences trades at a trailing P/E of 24.6. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 48.9.

### What is the ROE and ROCE of Eris Lifesciences?

Return on equity was 15.9% in FY26 and return on capital employed was 16.0% in FY26 (consolidated figures).

### Is Eris Lifesciences a debt-free company?

No. Eris Lifesciences' debt-to-equity ratio was 0.59 in FY26, with total debt of ₹956 Cr.

### What were Eris Lifesciences' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Eris Lifesciences reported revenue of ₹869 Cr, +12.6% year on year, and net profit of ₹144 Cr, +15.7% year on year.

### How has Eris Lifesciences stock performed over the last year?

Eris Lifesciences' share price has fallen 30.0% over the past year, −23.9% over three months and −16.7% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Eris Lifesciences?

As of 30 Jun 2026: promoters 54.14%, foreign institutions 5.75%, domestic institutions 20.72%, non-institutions 19.40%. 16.85% of promoter shares were pledged.

### Who are Eris Lifesciences' competitors?

The listed Pharma & Healthcare companies closest to Eris Lifesciences by market cap are Syngene International, Poly Medicure, Alembic Pharmaceuticals, Onesource Specialty Pharma, Alivus Life Sciences and AstraZeneca Pharma India.

### Is Eris Lifesciences a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Eris Lifesciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ERIS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.